The role of the ICOS-B7h T cell costimulatory pathway in transplantation immunity

Journal of Clinical Investigation

Volumn 112, Issue 2, 2003, Pages 234-243

  Harada, Hiroshi ^a   Salama, Alan D ^a,b   Sho, Masayuki ^a   Izawa, Atsushi ^a   Sandner, Sigrid E ^a   Ito, Toshiro ^b   Akiba, Hisaya ^c   Yagita, Hideo ^c   Sharpe, Arlene H ^b   Freeman, Gordon J ^d   Sayegh, Mohamed H ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; CD28 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; INDUCIBLE COSTIMULATORY MOLECULE; INTERLEUKIN 10; INTERLEUKIN 4; UNCLASSIFIED DRUG; CYTOKINE; ICOSL PROTEIN, MOUSE; LYMPHOCYTE ANTIGEN RECEPTOR; PROTEIN; STAT6 PROTEIN; STAT6 PROTEIN, MOUSE; TRANSACTIVATOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HISTOCOMPATIBILITY; IMMUNE RESPONSE; MAJOR HISTOCOMPATIBILITY COMPLEX; MINOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL; ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; BIOSYNTHESIS; C57BL MOUSE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOLOGY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; PHYSIOLOGY; SPLEEN; TIME;

ANIMALS; ANTIGENS, CD28; APOPTOSIS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GRAFT REJECTION; INTERFERON TYPE II; INTERLEUKIN-4; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PROTEINS; RECEPTORS, ANTIGEN, T-CELL; SIGNAL TRANSDUCTION; SPLEEN; STAT6 TRANSCRIPTION FACTOR; T-LYMPHOCYTES; TIME FACTORS; TRANS-ACTIVATORS;

EID: 0043245118     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200317008     Document Type: Article

References (65)

1. Sayegh, M.H., and Turka, L.A. 1998. The role of T-cell costimularory activation pathways in transplant rejection. N. Engl. J. Med. 338:1813-1821.
2. Salomon, B., and Bluestone, J.A. 2001. Complexities of CD28/B7: CTLA-4 costimulatory, pathways in autoimmunity and transplantation. Annu. Rev. Immunol. 19:225-252.
3. Coyle, A.J., and Gutierrez-Ramos, J.C. 2001. The expanding B7 superfamily: increasing complexity in costimulatory signals regulating T cell function. Nat. Immunol. 2:203-209.
4. Hancock, W.W., et al. 1996. Costimulatory Function and expression of CD40 ligand, CD80, and CD86 in vascularized murine cardiac allograft rejection. Proc. Natl. Acad. Sci. U. S. A. 93:13967-13972.
5. Grewal, I.S., and Flavell, R.A. 1998. CD40 and CD154 in cell-mediated immunity. Annu. Rev. Immunol. 16:111-135.
6. Larsen, C.P., et al. 1996. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature. 381:434-438.
7. Lin, H., et al. 1998. Cytotoxic T lymphocyte antigen 4 (CTLA-4) blockade accelerates the acute rejection of cardiac allografts in CD28-deficient mice: CTLA-4 can function independently of CD28. J. Exp. Med. 188:199-204.
8. Yamada, A., et al. 2001. CD28-independent costimulation of T cells in alloimmune responses. J. Immunol. 167:140-146.
9. Shimizu, K., Schonbeck, U., Mach, F., Libby, P., and Mitchell, R.N. 2000. Host CD40 ligand deficiency induces long-term allograft survival and donor-specific tolerance in mouse cardiac transplantation but does not prevent graft arteriosclerosis. J. Immunol. 165:3506-3518.
10. London, C.A., Lodge, M.P., and Abbas, A.K. 2000. Functional responses and costimulator dependence of memory CD4+ T cells. J. Immunol. 164:265-272.
11. Valujskikh, A., Pantenburg, B., and Heeger, P.S. 2002. Primed allospecific T cells prevent the effects of costimulatory blockade on prolonged cardiac allograft survival in mice. Am. J. Transplant. 2:501-509.
12. Ensminger, S.M., et al. 2000. CD8+ T cells contribute to the development of transplant arteriosclerosis despite CD154 blockade. Transplantation. 69:2609-2612.
13. Hutloff, A., et al. 1999. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature. 397:263-266.
14. McAdam, A.J., et al. 2001. ICOS is critical for CD40-mediated antibody class switching. Nature. 409:102-105.
15. Dong, C., et al. 2001. ICOS co-stimulator receptor is essential for T-cell activation and function. Nature. 409:97-101.
16. Dong, C., Temann, U.A., and Flavell, R.A. 2001. Cutting edge: critical role of inducible costimulator in germinal center reactions. J. Immunol. 166:3659-3662.
17. Tafuri, A., et al. 2001. ICOS is essential for effective T-helper-cell responses. Nature. 409:105-109.
18. McAdam, A.J., et al. 2000. Mouse inducible costimulatory molecule (ICOS) expression is enhanced by CD28 costimulation and regulates differentiation of CD4+ T cells. J. Immunol. 165:5035-5040.
19. Riley, J.L., et al. 2001. ICOS costimulation requires IL-2 and can be prevented by CTLA-4 engagement. J. Immunol. 166:4943-4948.
20. Swallow, M.M., Wallin, J.J., and Sha, W.C. 1999. B7h, a novel costimulatory homolog of B7.1 and B7.2, is induced by TNFalpha. Immunity. 11:423-432.
21. Yoshinaga, S.K., et al. 1999. T-cell co-stimulation through B7RP-1 and ICOS. Nature. 402:827-832.
22. Aicher, A., et al. 2000. Characterization of human inducible costimulator ligand expression and function. J. Immunol. 164:4689-4696.
23. Brodie, D., et al. 2000. LICOS, a primordial costimulatory ligand? Curr. Biol. 10:333-336.
24. Ling, V., et al. 2000. Cutting edge: identification of GL50, a novel B7-like protein that functionally binds to ICOS receptor. J. Immunol. 164:1653-1657.
25. Gonzalo, J.A., et al. 2001. Cutting edge: the related molecules CD28 and inducible costimulator deliver both unique and complementary signals required for optimal T cell activation. J. Immunol. 166:1-5.
26. Coyle, A.J., et al. 2000. The CD28-related molecule ICOS is required for effective T cell-dependent immune responses. Immunity. 13:98-105.
27. Sporici, R.A., and Perrin, P. J. 2001. Costimulation of memory T-cells by ICOS: a potential therapeutic target for autoimmunity? Clin. Immunol. 100:263-269.
28. Sperling, A.I., and Bluestone, J.A. 2001. ICOS costimulation: it's not just for TH2 cells anymore. Nat. Immunol. 2:573-574.
29. Greenwald, R.J., McAdam, A.J., Van Der Woude, D., Satoskar, A.R., and Sharpe, A.H. 2002. Cutting edge: inducible costimulator protein regulates both Th1 and Th2 responses to cutaneous leishmaniasis. J. Immunol. 168:991-995.
30. Ozkaynak, E., et al. 2001. Importance of ICOS-B7RP-1 costimulation in acute and chronic allograft rejection. Nat. Immunol. 2:591-596.
31. Carreno, B.M., and Collins, M. 2002. The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu. Rev. Immunol. 20:29-53.
32. Gonzalo, J.A., et al. 2001. ICOS is critical for T helper cell-mediated lung mucosal inflammatory responses. Nat. Immunol. 2:597-604.
33. Rottman, J.B., et al. 2001 The costimulatory molecule ICOS plays an important role in the immunopathogenesis of EAE. Nat. Immunol. 2:605-611.
34. Sporici, R.A., et al. 2001. ICOS ligand costimulation is required for T-cell encephalitogenicity. Clin. Immunol. 100:277-288
35. Ogawa, S., et al. 2001. Opposing effects of anti-activation-inducible lymphocyte-immunomodulatory molecule/inducible costimulator antibody on the development of acute versus chronic graft-versus-host disease. J. Immunol. 167:5741-5748.
36. Iwai, H., et al. 2002. Amelioration of collagen-induced arthritis by blockade of ICOS-B7h costimulation. J. Immunol. 169:4332-4339.
37. Walunas, T.L., et al. 1994. CTLA-4 can function as a negative regulator of T cell activation. Immunity. 1:405-413.
38. Corry, R.J., Winn, H.J., and Russell, P.S. 1973. Primarily vascularized allografts of hearts in mice. The role of H-2D, H-2K, and non-H-2 antigens in rejection. Transplantation. 16:343-350.
39. Matesic, D., Lehmann, P.V., and Heeger, P.S. 1998. High-resolution characterization of cytokine-producing alloreactivity in naive and allograft-primed mice. Transplantation. 65:906-914.
40. Kishimoto, K. et al. 2000. The role of CD154-CD40 versus CD28-B7 costimulatory pathways in regulating allogeneic Th1 and Th2 responses in vivo. J. Clin. Invest. 106:63-72.
41. Sho, M., et al. 2002. New insights into the interactions between T cell costimulatory blockade and conventional immunosuppressive drugs. Ann. Surg. 236:667-675.
42. Zhai, Y., et al. 2002. The CD154-CD40 T cell costimulation pathway is required for host sensitization of CD8(+) T cells by skin grafts via direct antigen presentation. J. Immunol. 169:1270-1276.
43. Marsh, J.E., et al. 2001. The allogeneic T and B cell response is strongly dependent on complement components C3 and C4. Transplantation. 72:1310-1318.
44. Backstrom, B.T., Muller, U., Hausmann, B., and Palmer, E. 1998. Positive selection through a motif in the alphabeta T cell receptor. Science. 281:835-838.
45. Sayegh, M.H., et al. 2003. Allograft rejection in a new allospecific CD4+ TCR transgenic mouse. Am. J. Transplant. 3:381-389.
46. Sandner, S.E., et al. 2003. The first model of tracking allospecific CD4+ T cell activation and tolerance in vivo. Am. J. Transplant. In press.
47. Suchin, E.J., et al. 2001. Quantifying the frequency of alloreactive T cells in vivo: new answers to an old question. J. Immunol. 166:973-981.
48. Sho, M., et al. 2002. Physiological mechanisms of regulating alloimmunity: cytokines, CTLA-4, CD25+ cells, and the alloreactive T cell clone size. J. Immunol. 169:3744-3751.
49. Kopf, M., et al. 2000. Inducible costimulator protein (ICOS) controls T helper cell subset polarization after virus and parasite infection. J. Exp. Med. 192:53-61.
50. Wallin, J.J., Liang, L., Bakardjiev, A., and Sha, W.C. 2001. Enhancement of CD8+ T cell responses by ICOS/B7h costimulation. J. Immunol. 167:132-139.
51. Liu, X., et al. 2001. B7H costimulates clonal expansion of, and cognate destruction of tumor cells by, CD8(+) T lymphocytes in vivo. J. Exp. Med. 194:1339-1348.
52. Jones, H.P., Tabor, L., Sun, X., Woolard, M.D., and Simecka, J.W. 2002. Depletion of CD8+ T cells exacerbates CD4+ Th cell-associated inflammatory lesions during murine mycoplasma respiratory disease. J. Immunol. 168:3493-3501.
53. Gilliet, M., and Lin, Y.J. 2002. Generation of human CD8 T regulatory cells by CD40 ligand-activated plasmacytoid dendritic cells. J. Exp. Med. 195:695-704.
54. Chang, C.C., et al. 2002. Tolerization of dendritic cells by T(S) cells: the crucial role of inhibitory receptors ILT3 and ILT4. Nat. Immunol. 3:237-243.
55. Colovai, A.I., et al. 2003. Regulatory CD8+CD28- T cells in heart transplant recipients. Hum. Immunol. 64:31-37.
56. Lin, H., et al. 1998. Cytotoxic T lymphocyte antigen 4 (CTLA-4) blockade accelerates the acute rejection of cardiac allografts in CD28-deficient mice: CTLA-4 can function independently of CD28. J. Exp. Med. 188:199-204.
57. Salama, A.D., et al. 2003. The interaction between ICOS-B7RP1 and CD28-B7 costimulatory pathways in alloimmune responses in vivo. Am. J. Transplant. 3:390-395.
58. Guo, J., et al. 2001. Stimulatory effects of B7-related protein-1 on cellular and humoral immune responses in mice. J. Immunol. 166:5578-5584.
59. Guo, L., et al. 2002. Prolonged survival in rat liver transplantation with mouse monoclonal antibody against an inducible costimulator (ICOS). Transplantation. 73:1027-1032.
60. Nurieva, R.I., Treuting, P., Duong, J., Flavell, R.A., and Dong, C. 2003. Inducible costimulator is essential for collagen-induced arthritis. J. Clin. Invest. 111:701-706. doi:10.1172/JCI200317321.
61. Greenwald, R.J., Latchman, Y.E., and Sharpe, A.H. 2002. Negative coreceptors on lymphocytes. Curr. Opin. Immunol. 14:391-396.
62. Akbari, O., et al. 2002. Antigen-specific regulatory T cells develop via the ICOS-ICOS-ligand pathway and inhibit allergen-induced airway hyperreactivity. Nat. Med. 8:1024-1032.
63. Jiang, H., Braunstein, N.S., Yu, B., Winchester, R., and Chess, L. 2001. CD8+ T cells control the TH phenotype of MBP-reactive CD4+ T cells in EAE mice. Proc. Natl. Acad. Sci. U. S. A. 98:6301-6306.
64. Yamada, A., Salama, A.D., and Sayegh, M.H. 2002. The role of novel T cell costimulatory pathways in autoimmunity and transplantation. J. Am. Soc. Nephrol. 13:559-575.
65. Salama, A.D., and Sayegh, M.H. 2003. Alternative T-cell costimulatory pathways in transplant rejection and tolerance induction: hierarchy or redundancy? Am. J. Transplant. 3:509-511.